Global eradication of poliovirus remains elusive, and it is critical to develop next generation vaccines and antivirals. In support of this goal, we map the epitope of human monoclonal antibody 9H2 which is able to neutralize the three serotypes of poliovirus. Using cryo-EM we solve the near-atomic structures of 9H2 fragments (Fab) bound to capsids of poliovirus serotypes 1, 2, and 3. The Fab-virus complexes show that Fab interacts with the same binding mode for each serotype and at the same angle of interaction relative to the capsid surface. For each of the Fab-virus complexes, we find that the binding site overlaps with the poliovirus receptor (PVR) binding site and maps across and into a depression in the capsid called the canyon. No conformational changes to the capsid are induced by Fab binding for any complex. Competition binding experiments between 9H2 and PVR reveal that 9H2 impedes receptor binding. Thus, 9H2 outcompetes the receptor to neutralize poliovirus. The ability to neutralize all three serotypes, coupled with the critical importance of the conserved receptor binding site make 9H2 an attractive antiviral candidate for future development.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10564760 | PMC |
http://dx.doi.org/10.1038/s41467-023-41052-9 | DOI Listing |
Cureus
November 2024
Internal Medicine, Ishikawa Prefectural Central Hospital, Kanazawa, JPN.
Sci Total Environ
December 2024
Faculty of Mathematics and Physics, Charles University, Sokolovska 49, 186 75 Prague, Czech Republic.
In many countries worldwide, NO emissions currently decrease as a result of pollution control, while NH emissions stagnate or continue to increase. Little is known about horizontal deposition of NO and NH, the oxidation/neutralization products of these primary pollutants. To close the knowledge gap, we studied atmospheric inputs of NO and NH at two mountain-top sites near the Czech-German-Polish borders during winter.
View Article and Find Full Text PDFExpert Rev Vaccines
December 2024
Guangzhou Patronus Biotech Co, Ltd, Guangzhou, China.
Background: LYB001 is a recombinant protein COVID-19 vaccine displaying a receptor-binding domain (RBD) in a highly immunogenic array on virus-like particles (VLPs). This study assessed the immunogenicity and safety of LYB001 as a booster.
Research Design And Methods: In this randomized, active-controlled, double-blinded, phase 3 trial, participants aged ≥18 years received a booster with LYB001 or ZF2001 (Recombinant COVID-19 Vaccine).
Commun Biol
December 2024
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia.
Study of mechanisms by which antibodies recognize different viral strains is necessary for the development of new drugs and vaccines to treat COVID-19 and other infections. Here, we report 2.5 Å cryo-EM structure of the SARS-CoV-2 Delta trimeric S-protein in complex with Fab of the recombinant analog of REGN10987 neutralizing antibody.
View Article and Find Full Text PDFEnviron Res
December 2024
School of Chemistry and Chemical Engineering, Guangxi Minzu University. Nanning 530006 China.
At present, the mechanism difference between tetragonal BiVO (t-BiVO) and monoclinic BiVO (m-BiVO) coupled peroxymonosulfate (PMS) to realize photocatalysis is still unclear. In this study, m-BiVO and t-BiVO were obtained by adjusting the bismuth-vanadium ratio in the precursor solution (Bi:V = 3:1; 1:1; 1:2 and 1:3). The results of photocatalytic experiments showed that both t-BiVO and m-BiVO had certain activation effects on PMS, and the prepared monoclinic B1V2 has the strongest photocatalytic performance.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!